Dr. Neeha Zaidi, MD

Dr. Zaidi practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Zaidi's NPI, 1295091841, was assigned on April 9, 2012. Dr. Zaidi graduated from Icahn School of Medicine at Mount Sinai in 2012. Dr. Zaidi holds Maryland license D81282.

Dr. Zaidi's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Zaidi's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Zaidi is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Zaidi to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zaidi practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zaidi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zaidi is licensed in Maryland.

CMS data shows 40 Medicare services from Dr. Zaidi across 2 procedure codes in 2024, all of them office visits, for 49 Medicare patients. Medicare paid $3,200 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 49 Medicare patients who saw Dr. Zaidi in 2024. The largest group is 65 to 74, with 22 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zaidi's median patient age at 71, with 63% women.

In 2024, Dr. Zaidi wrote 87 Medicare Part D claims. 59% of them were for generic drugs. CMS names the drug for 42 of them, across 3 drugs with 11 or more claims each, at $70,705 in total drug cost. In 2023, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Zaidi for performance year 2024, reported as part of a group. CMS lists Dr. Zaidi as offering telehealth.

Dmand AI links 45 papers to Dr. Zaidi, published from 2011 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Immunotherapy, Cancer Vaccines and Pancreatic Neoplasms. Dr. Zaidi has published most often in JCI Insight. Dr. Zaidi's most frequent co-authors are Elizabeth Jaffee, MD, Daniel Alexander Laheru, MD and Nilofer Saba Azad, MD.

Dmand AI links Dr. Zaidi to 2 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Colonic Neoplasms and Pancreatic Diseases. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 2.

CMS Open Payments shows 4 general payments to Dr. Zaidi from 3 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 98% of the total. Genentech, Inc. paid the most, $3,800. It also lists 3 research payments totaling $3,587 from 2023 to 2024.

Dr. Zaidi graduated from Icahn School of Medicine at Mount Sinai in 2012.